Genomind Demonstrates Broader Commitment To The Mental Health Community

Genomind Demonstrates Broader Commitment To The Mental Health Community

Presence expanded at the American Psychiatric Association (APA) Annual Meeting this week

CHALFONT, PA – May 17, 2013 – Genomind, a personalized medicine company, is pleased to announce that we will attend and present at the American Psychiatric Association (APA) Annual Meeting, held May 18 – 22, 2013, in San Francisco at the Moscone Center. The APA Annual Meeting is a hands-on learning convention designed to help practicing professionals in all levels of psychiatric research and care connect, learn, and improve

Genomind will host a variety of opportunities to showcase our innovative saliva-based genetic test, the Genecept™ Assay; demonstrate the highlights of our new Genomind Portal and Open Label Study; and educate psychiatric professionals on our dedication to harnessing the latest research to better treat patients.

Product Theater: On Monday, May 20, from 1-2 PM, Genomind will offer our first Product Theater for APA attendees with a session titled, “The Link Between Mental and Physical Health: Using Genetics to Treat the Whole Patient.” The session will be lead by Dr. Jay Lombard, Chief Scientific Officer and Medical Director of Genomind, and talking points will include the Assay’s use in the market today, how Assay results can help clinicians create personalized treatment options, and how a patient-centric approach can help uncover when physical disorders may be mimicking a mental illness. The Product Theater session will be held in the Moscone Center, South Building, Hall C, at Booth #2326.

Booth #933: Genomind will be available on the main show floor at Booth #933 in the Moscone Center with a new, expanded 20×20 informational booth. We encourage all attendees to stop by to connect with us and learn more about our innovative product and programs.

NAMI Roundtable: In addition to the Genomind sponsored events, the company will also participate in the NAMI (National Alliance on Mental Illness) “Emerging Technologies Roundtable Discussion” where Dr. Lombard will educate NAMI executives and advocates about the use of the test and how it can benefit NAMI members.

Clinical TMS Society: On Saturday, May 18, at 6:30 pm, Genomind will join the Clinical TMS Society and participate in a poster session, during which we will share our innovative Open Label Study design for the Genecept™ Assay. The session will be held at the InterContinental San Francisco.

About the Genecept Assay

The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/.

About Genomind

Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.

For more information, contact:

Adam Shapiro
ASPR
202-427-3603
Adam.Shapiro@ASPR.bz

Amy Pressman
Marketing Manager, Genomind
267-532-8866
apressman@genomind.com